← Leaderboards
Tracey Rogers
National Center For Advancing Translational Sciences
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Most similar at National Center For Advancing Translational Sciences
Same institution · by research overlap
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsManufactureFormulationSide EffectInvestigational New Drug ApplicationToxicologyLeadClinical TrialsPre-ClinicalDosePreclinical DevelopmentPainBrainUnited States Food And Drug AdministrationIn VivoTechnologyDrug KineticsEvaluationExcipientsEfficacy StudyBindingFirst-In-HumanClinical ResearchOperative Surgical Procedures
Grant awards (11)
Fast, Centrally Acting, Non-Addicting Novel Analgesic for Chronic Non-Cancer Pain$1,307,330
ZIA · FY2025 · TR · contact PI
Targeted Bone Regeneration via Activation of Resident Stem Cells$982,825
ZIA · FY2025 · TR · contact PI
Development of a CoQ10 Headgroup Intermediate (4-HB) to Treat a Novel Pediatric Mitochondrial Encephalopathy$947,723
ZIA · FY2025 · TR · contact PI
Formulation of Inhaled Bethanechol to Treat Excessive Dynamic Airway Collapse$554,924
ZIA · FY2025 · TR · contact PI
Targeted Bone Regeneration via Activation of Resident Stem Cells$2,066,904
ZIA · FY2024 · TR · contact PI
Fast, Centrally Acting, Non-Addicting Novel Analgesic for Chronic Non-Cancer Pain$1,874,696
ZIA · FY2024 · TR · contact PI
Developing ORC-13661 for Preventing Aminoglycoside Antibiotics-induced Hearing Loss$1,066,904
ZIA · FY2024 · TR · contact PI
Development of Drinabant for Treatment of Acute Cannabinoid Overdose$1,066,904
ZIA · FY2024 · TR · contact PI
Targeted Bone Regeneration via Activation of Resident Stem Cells$2,820,500
ZIA · FY2023 · TR · contact PI
Development of Drinabant for Treatment of Acute Cannabinoid Overdose$1,300,250
ZIA · FY2023 · TR · contact PI
Developing ORC-13661 for Preventing Aminoglycoside Antibiotics-induced Hearing Loss$1,202,536
ZIA · FY2023 · TR · contact PI